Holen Sie sich die Stockscreener-App
0.00
100.00%
-104.91
Schlusskurs vom Vortag:
$104.91
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$20.03B
Einnahmen:
$3.25B
Nettoeinkommen (Verlust:
$-207.95M
KGV:
0.00
EPS:
-1.1046
Netto-Cashflow:
$356.78M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
EXAS Technical Analysis & Stock Price Forecast - Intellectia AI
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - AD HOC NEWS
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Exact Sciences Completes Enrollment of DeeP-C Clinical Trial for Colorectal Cancer Screening - yahoo.com
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History - GuruFocus
Exact Sciences (NASDAQ: EXAS) files Form 15 to suspend certain SEC reporting duties - Stock Titan
Exact Sciences Corp (EXK.DU) stock price, news, quote and history - Yahoo Finance UK
Excelerate Energy Stock: Leading Provider of LNG Infrastructure Faces Evolving Global Energy Demands - AD HOC NEWS
EXAS PE Ratio & Valuation, Is EXAS Overvalued - Intellectia AI
Cinctive Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares - Stock Titan
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Insider Monkey
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update - AD HOC NEWS
Privia Health screening program increases colorectal cancer screening rates - MSN
Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition - CoinCentral
Abbott closes $23 billion deal to buy Madison-based Exact Sciences - Yahoo Finance
EXAS Receives Neutral Rating from BTIG's Mark Massaro | EXAS Sto - GuruFocus
Abbott completes Exact Sciences acquisition - MassDevice
Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist - tradingview.com
Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott Acquires Exact Sciences to Lead Cancer Screening and Diagnostics Market - Minichart
Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026 - Minichart
Abbott completes acquisition of Exact Sciences By Investing.com - Investing.com Canada
Exact Sciences Corp. stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott completes acquisition of Exact Sciences - Investing.com
Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq - Investing.com
Exact Sciences (EXAS) director has equity cancelled and cashed out at $105 per share in Abbott merger - Stock Titan
Abbott’s buyout of Exact Sciences (EXAS) cashes out director’s shares - stocktitan.net
Abbott buys Exact Sciences (NASDAQ: EXAS) in $105-per-share cash merger - Stock Titan
Abbott buyout sees Exact Sciences (EXAS) director surrender all shares - Stock Titan
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening - intellectia.ai
Exact Sciences Amends Convertible Notes; Post-Merger Conversions Payable in Cash at $105 Per Share - TradingView
Abbott buys Exact Sciences (NASDAQ: EXAS) in $21B cash deal - Stock Titan
Abbott (NYSE: ABT) closes Exact Sciences cancer diagnostics deal - Stock Titan
Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges - AD HOC NEWS
Exact Sciences Corporation (EXAS) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment Story - Yahoo Finance
The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout - simplywall.st
Abbott to close Exact Sciences acquisition on March 23 By Investing.com - Investing.com South Africa
Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures - Kalkine Media
Exact Sciences and Abbott receive all approvals for planned merger By Investing.com - Investing.com India
Abbott Laboratories to close $21B Exact Sciences deal Monday - Modern Healthcare News
When Abbott Labs expects to close on $23B takeover of Exact Sciences - The Business Journals
Exact Sciences Corp Announces Merger Agreement with Abbott Laboratories – SEC 8-K Filing March 2026 - minichart.com.sg
Abbott to close $21B Exact Sciences acquisition Monday - MedTech Dive
Abbott to close Exact Sciences acquisition on march 23 - Investing.com
Abbott to close Exact Sciences acquisition on March 23 - investing.com
Exact Sciences and Abbott receive all approvals for planned merger - Investing.com
Exact Sciences Nears Completion of Abbott Acquisition Deal - TipRanks
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):